Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
CognitiveInvestigational

N-acetyl Selank Amidate

Intranasal
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

N-acetyl Selank Amidate is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin, modified with acetylation and amidation to increase half-life and central nervous system activity. It is reported to exert anxiolytic and nootropic effects through modulation of enkephalin metabolism and influencing monoamine neurotransmitter systems without sedation or dependency.

Mechanism of Action

The peptide has been explored for anxiety, cognitive enhancement, and stress adaptation.

Research Summary & Key Findings

Preclinical studies in rodents have shown anxiolytic effects comparable to benzodiazepines but without adverse effects on motor coordination or memory, with publications in behavioral pharmacology journals. Small clinical studies conducted in Russia have reported subjective improvements in anxiety and cognitive performance, but these lack the rigor and replication of international randomized trials. The compound is not approved by major Western regulatory agencies.

Clinical Status

Investigational

N-acetyl Selank Amidate is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intranasal

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Cognitive

No lawful pathway today

N-acetyl Selank Amidate is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.